RT Journal Article
SR Electronic
T1 Epidemiological Development of Novel Coronavirus Pneumonia in China and Its Forecast
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.21.20026229
DO 10.1101/2020.02.21.20026229
A1 Wu, Shanshan
A1 Sun, Panpan
A1 Li, Ruiling
A1 Zhao, Liang
A1 Wang, Yanli
A1 Jiang, Lifang
A1 Wang, Haili
A1 Deng, Jinbo
YR 2020
UL http://medrxiv.org/content/early/2020/02/26/2020.02.21.20026229.abstract
AB BACKGROUND AND OBJECTIVE The novel coronavirus (SARS-Cov-2) infected coronavirus disease 2019 (COVID-19) was broken out in Wuhan and Hubei province for more than a month. It severely threats people’s health of thousands in Chin and even other countries. In order to prevent its wide spread, it is necessary to understand the development of the epidemic with precise mathematical language.METHODS The various data of novel coronavirus pneumonia were collected from the official websites of the National Health Committee of the People’s Republic of China. According to epidemic and administrative division, three groups were divided to analyze the data, Hubei Province (including Wuhan), nationwide without Hubei and Henan Province. With classic SIR models, the fitting epidemiological curves of incidence have made, and basic reproduction number (R0) was also calculated as well. Therefore the disease’s infection intensity, peak time and the epidemiological end time can be deduced.RESULTS (1) Wuhan was the origin place of the epidemic, then it spread to Hubei province quickly. The patients in Hubei had increased rapidly with exponential rise. According to data in Hubei province, the fitting parabolas were made, and some with 51,673 cases. R0 curve shows with S-curve, at early breakout, R0 was as high as 6.27, then it decrease gradually. It is expected to approach to zero in early May; (2) In the group of nationwide without Hubei, the patient cases were much lower than Hubei, but its epidemiological fitting curve also shows a parabola as Hubei. The peak will arrive around February 10 with 9,145 cases. At beginning, R0 was as high as 2.44, then it decreases gradually and approach to zero in the end of March. (3) In Henan Province, the incidence stays very low, the parabolic fitting curve is similar to the nationwide without Hubei. The epidemic is expected to reach the peak on around February 12 and end in early April.CONCLUSION The epidemic development in all three groups shows parabolic curves. Their incidences are expected to reach their peaks on February 18 in Hubei, on February 10 in other areas of China. The epidemic will end in early May in Hubei, and in early April in other areas of China. Our study may provide useful knowledge for the government to make prevention and treatment policies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding:This study was supported by Scientific and Technical Project of Henan Science and Technology Department (192102310134), Open Project of National Health Commission Key Laboratory of Birth Defect Prevention (ZD201903) and Medical Foundation of Health and Family Planning Commission of Henan Province (No. 2018020589)Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDissemination to participants and related patient and public communities: No study participants were involved in the preparation of this article, which permits others to distribute, adapt and build upon this article noncommercially.